Search

Your search keyword '"Dermitzaki, Eleni"' showing total 37 results
Start Over Author "Dermitzaki, Eleni"
37 results on '"Dermitzaki, Eleni"'

10. Treatment of alopecia totalis/universalis/focalis with vitamin D and analogs: Three case reports and a literature review

Author

Papadimitriou, Dimitrios T; https://orcid.org/0000-0002-6083-3560, Bothou, Christina; https://orcid.org/0000-0003-3840-7140, Dermitzaki, Eleni; https://orcid.org/0000-0001-9264-2606, Alexopoulos, Alexios; https://orcid.org/0000-0002-6742-9229, Mastorakos, George; https://orcid.org/0000-0002-1929-3275, Papadimitriou, Dimitrios T; https://orcid.org/0000-0002-6083-3560, Bothou, Christina; https://orcid.org/0000-0003-3840-7140, Dermitzaki, Eleni; https://orcid.org/0000-0001-9264-2606, Alexopoulos, Alexios; https://orcid.org/0000-0002-6742-9229, and Mastorakos, George; https://orcid.org/0000-0002-1929-3275

Abstract

BACKGROUND: Alopecia areata (AA) is an inflammatory disease with autoimmune, environmental, and inherited components directed at the hair follicle, either limited to patchy hair loss over the scalp (Focalis, AF), total loss of scalp hair (Totalis, AT), or total loss of both scalp and body hair (Universalis, AU). Despite multiple treatment modalities, no therapy exists. Vitamin D deficiency in patients with AA/AT/AF influences disease severity and duration, inversely correlating with inflammation histologically. CASE SUMMARY: Three girls presented with AT (P1), AU (P2), and AF (P3) at the ages of 1, 5, and 5 years, respectively. For P1-P2, all available treatments implemented for 2 years had failed. We started an initial 6-mo repletion with oral cholecalciferol 2000/4000 IU/d, with no apparent effect. Then we attempted immunomodulation using oral calcitriol and its analog paricalcitol. On calcitriol, 0.5 mcg/d P1 regrew hair within 6 mo. After 4 years, a relapse with loss of eyebrow hair was resolved after doubling the calcitriol dose to 0.5 mcg × 2/d; the results have been maintained for 6 years to date. On calcitriol, 0.25 mcg × 3/d P2 led to the development of asymptomatic hypercalcemia-hypercalciuria, which was immediately resolved by switching to paricalcitol 2 mcg × 3/d; mild tolerable hypercalciuria was maintained. Hair regrowth was observed at 6 mo, stabilizing only as fur at 12 mo. AF in P3 was resolved completely within 3 mo on a daily high dose (8000 IU) of cholecalciferol. CONCLUSION: Vitamin D may have immunomodulating therapeutic impact on AT/AU/AF, which needs to be explored with further pilot clinical trials.

Published
2021

14. Lessons from Wolfram Syndrome: Initiation of DDAVP Therapy Causes Renal Salt Wasting Due to Elevated ANP/BNP Levels, Rescued by Fludrocortisone Treatment

Author

Kleanthous, Kleanthis, primary, Maratou, Eirini, additional, Spyropoulou, Dora, additional, Dermitzaki, Eleni, additional, Papadimitriou, Anastasios, additional, Zoupanos, George, additional, Moutsatsou, Paraskevi, additional, Mastorakos, George, additional, Urano, Fumihiko, additional, and Papadimitriou, Dimitrios T., additional

Published
2020
Full Text
View/download PDF

15. RANKL promotes the expansion of mammary epithelial cells in osteoporotic TgRANKL mouse models

Author

Kolokotroni, Anthi, primary, Rinotas, Vagelis, additional, Gkikopoulou, Evi, additional, Efstathiou, Eirini, additional, Dermitzaki, Eleni, additional, Rentis, Thanasis, additional, Zareifi, Danae, additional, Lymperopoulos, Ilias, additional, Samiotaki, Martina, additional, Alexopoulos, Leonidas, additional, Panayotou, George, additional, and Douni, Eleni, additional

Published
2020
Full Text
View/download PDF

25. Successful Treatment of Severe Atopic Dermatitis with Calcitriol and Paricalcitol in an 8-Year-Old Girl

Author

Bothou, Christina Alexopoulos, Alexis Dermitzaki, Eleni and Kleanthous, Kleanthis Papadimitriou, Anastasios Mastorakos, George Papadimitriou, Dimitrios T.

Abstract

Atopic dermatitis (AD) is a chronic inflammatory disease affecting children and adolescence. The traditional therapeutic options for AD, including emollients topically and immune modulatory agents systemically focusing on reducing skin inflammation and restoring the function of the epidermal barrier, are proven ineffective in many cases. Several studies have linked vitamin D supplementation with either a decreased risk to develop AD or a clinical improvement of the symptoms of AD patients. In this report, we present a girl with severe AD who under adequate supplementation with cholecalciferol was treated with calcitriol and subsequently with paricalcitol. She had significant improvement-almost healing of her skin lesions within 2 months, a result sustained for more than 3 years now. Because of hypercalciuria as a side effect from calcitriol therapy, treatment was continued with paricalcitol, a vitamin D analogue used in secondary hyperparathyroidism in chronic kidney disease. Calcitriol therapy may be considered as a safe and efficacious treatment option for patients with severe AD, particularly for those with refractory AD, under monitoring for possible side effects. Treatment with paricalcitol resolves hypercalciuria, is safe, and should be further investigated as an alternative treatment of atopic dermatitis and possibly other diseases of autoimmune origin.

Published
2018

26. P1-P201 Anastrozole is Safe as Monotherapy in Early Maturing Girls with Compromised Growth, Further Improving Gain in Predicted Adult Height by the Initial Combination Therapy of an LHRH Analogue and an Aromatase Inhibitor. Results from the 'GAIL' Study ISRCTN11469487

Author

Darendeliler, Feyza, Dermitzaki, Eleni, Kleanthous, Kleanthis, Papagianni, Maria, Attilakos, Achilleas, Mastorakos, George, Papadimitriou, Anastasios, and Papadimitriou, Dimitrios T

Published
2018
Full Text
View/download PDF

27. RFC13.4 Gain in predicted adult height using the combination of an LHRH analogue and an aromatase inhibitor in early maturing girls with compromised growth for 2 yrs or until the age of 11 is maintained and further improved by aromatase inhibitor monotherapy. Results on final height of the 'GAIL' study ISRCTN11469487

Author

Papadimitriou, Dimitrios T, Dermitzaki, Eleni, Papagianni, Maria, Kleanthous, Kleanthis, Attilakos, Achilleas, Mastorakos, George, and Papadimitriou, Anastasios

Published
2018
Full Text
View/download PDF

30. Successful treatment of severe atopic dermatitis with calcitriol and paricalcitol in an 8-year-old girl

Author

Soliman, Ashraf, Bothou, Christina, Alexopoulos, Alexis, Dermitzaki, Eleni, Kleanthous, Kleanthis, Papadimitriou, Anastasios, Mastorakos, George, Papadimitriou, Dimitrios, Soliman, Ashraf, Bothou, Christina, Alexopoulos, Alexis, Dermitzaki, Eleni, Kleanthous, Kleanthis, Papadimitriou, Anastasios, Mastorakos, George, and Papadimitriou, Dimitrios

Abstract

Atopic dermatitis (AD) is a chronic inflammatory disease affecting children and adolescence. The traditional therapeutic options for AD, including emollients topically and immune modulatory agents systemically focusing on reducing skin inflammation and restoring the function of the epidermal barrier, are proven ineffective in many cases. Several studies have linked vitamin D supplementation with either a decreased risk to develop AD or a clinical improvement of the symptoms of AD patients. In this report, we present a girl with severe AD who under adequate supplementation with cholecalciferol was treated with calcitriol and subsequently with paricalcitol. She had significant improvement—almost healing of her skin lesions within 2 months, a result sustained for more than 3 years now. Because of hypercalciuria as a side effect from calcitriol therapy, treatment was continued with paricalcitol, a vitamin D analogue used in secondary hyperparathyroidism in chronic kidney disease. Calcitriol therapy may be considered as a safe and efficacious treatment option for patients with severe AD, particularly for those with refractory AD, under monitoring for possible side effects. Treatment with paricalcitol resolves hypercalciuria, is safe, and should be further investigated as an alternative treatment of atopic dermatitis and possibly other diseases of autoimmune origin.

Published
2018

34. Overweight and obesity decreased in Greek schoolchildren from 2009 to 2012 during the early phase of the economic crisis

Author

Kleanthous, Kleanthis Dermitzaki, Eleni Papadimitriou, Dimitrios T. Papaevangelou, Vassiliki Papadimitriou, Anastasios

Abstract

Aim: We examined the weight status of Greek schoolchildren from November 2009 to May 2012, shortly before, and during the early years, of the Greek economic crisis. Methods: This was a mixed longitudinal study that formed part of the West Attica Growth Study and followed children at the ages of 6-7, 9-10, 12-13 and 15-16 years every six months for 2.5 years. Each child’s height and weight were measured and their body mass index calculated. We were able to determine the weight status of 1327 children (53% boys) based on their first and last measurements. Overweight, obesity and underweight were defined using the International Obesity Task Force criteria. Results: During the 2.5-year study period, there was a decrease in the total prevalence of overweight and obesity, which reached a statistical significance for both sexes. It decreased from 43% to 37.3% (p = 0.02) in boys and from 33.4% to 26.9% (p = 0.0056) in girls. There was also a statistically significant increase in normal weight children and a slight but insignificant increase in underweight children of both sexes. Conclusion: During the initial years of the Greek economic crisis, there was a statistically significant reduction in overweight and obesity in children from six to 16 years of age.

Published
2016

Catalog

Books, media, physical & digital resources
See catalog results